The Clinical Development Team at BridgeBio Oncology Therapeutics is responsible for the design, implementation, and oversight of clinical trials aimed at evaluating the safety and efficacy of novel small molecule therapeutics targeting RAS and PI3K oncogenes. This interdisciplinary team collaborates closely to ensure that the development processes are aligned with regulatory standards, while also focusing on optimizing patient outcomes through innovative clinical strategies. They play a critical role in advancing the company's pipeline from preclinical stages through to clinical proof of concept.